Adeshwar Meditex Ltd operates in Healthcare Research, Analytics & Technology within the Healthcare sector.
434 historical price candles were omitted because the exchange source has not been verified.
No positive flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
| Holder (%) | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| 57.55% | 57.55% | 57.55% | 57.68% | |
| FII | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% |
| 42.45% | 42.45% | 42.45% | 42.32% | |
| No. of shareholders | 182 | 188 | 187 | 192 |
Promoter holding up 0.13 percentage points since Sep 2024.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Standalone figures
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross margin % | 17.1% | 15.2% | 15.6% | 12.6% | 11.1% | 16.2% |
| EBITDA margin % | 7% | 5.2% | ||||
| 6.3% |
| 6.5% |
| 5.2% |
| 4.9% |
| EBIT margin % | 6.5% | 4.6% | 5.6% | 5.7% | 4.6% | 4.2% |
| PAT margin % | 2.6% | 1.2% | 2.5% | 2.5% | 2.5% | 2.3% |
| Working capital | ||||||
| Receivable days | — | — | — | — | — | — |
| Inventory days | 174 | 168 | 128 | 139 | 127 | 159 |
| Payable days | — | — | — | — | — | — |
| NWC days | — | — | — | — | — | — |
| Leverage | ||||||
| Current ratio | 1.59 | 1.76 | 1.9 | 2.06 | 2.03 | 4.52 |
| Debt to EBITDA | — | — | — | — | — | — |
| Debt to equity | — | — | — | — | — | — |
| Interest coverage | 2.1 | 1.6 | 2.4 | 2.4 | 3.1 | 4 |
| Asset turnover | 1.06 | 0.89 | 1.23 | 1.25 | 1.16 | 1.12 |
| Return ratios | ||||||
| Return on assets % | 2.7% | 1.1% | 3.1% | 3.1% | 2.9% | 2.5% |
| Return on capital employed % | 17.1% | 10.4% | 13.9% | 13.1% | 10.9% | 6.1% |
| Return on equity % | — | — | — | — | — | — |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Syngene International LimitedSYNGENESYNGENE | ₹14,586 Cr | ₹14,595 Cr | ₹3,600 Cr | ₹803 Cr | 24.6% | ₹221 Cr | 8.5% | 9.8% | 6.6% | -32 |
| Indegene LimitedINDGNINDGN | ₹14,303 Cr | ₹14,303 Cr | ₹3,813 Cr | ₹638 Cr | 17.6% | ₹401 Cr | 11.4% | 17.9% | 13.9% | 79 |
| Suven Life Sciences LimitedSUVENSUVEN | ₹8,139 Cr | ₹8,139 Cr | ₹9 Cr | ₹-366 Cr | — | ₹-352 Cr | — | -78.4% | -78.8% | 72 |
| Vimta Labs LimitedVIMTALABSVIMTALABS | ₹2,612 Cr | ₹2,631 Cr | ₹336 Cr | ₹112 Cr | 27.3% | ₹61 Cr | 12.9% | 17.4% | 13.6% | 179 |
| Bilcare LimitedBIBI | ₹227 Cr | ₹896 Cr | ₹788 Cr | ₹45 Cr | 5.7% | ₹-29 Cr | -7.1% | 1.5% | -6% | 78 |
| Take Solutions LimitedTAKETAKE | ₹187 Cr | ₹187 Cr | ₹85 Cr | ₹-2 Cr | -3.5% | ₹13 Cr | 20% | 18.5% | 42.1% | -7 |
| Jeevan Scientific Technology LtdJSTLJSTL | ₹169 Cr | ₹186 Cr | ₹62 Cr | ₹10 Cr | 16% | ₹0 Cr | 1.7% | 5.4% | 1.7% | -109 |
| Novelix Pharmaceuticals LtdNOVELIXNOVELIX | ₹167 Cr | ₹167 Cr | ₹9 Cr | ₹-3 Cr | -29.9% | ₹-2 Cr | -23.6% | -28.1% | -28.5% | 57 |
| Globalspace Technologies LtdGSTLGSTL | ₹103 Cr | — | ₹25 Cr | ₹11 Cr | 5.9% | ₹7 Cr | -1.4% | — | — | — |
| Adeshwar Meditex LtdADESHWARADESHWAR | ₹23 Cr | — | ₹56 Cr | ₹3 Cr | 4.9% | ₹1 Cr | 2.3% | — | — | — |
| Vanta Bioscience LtdVANTABIOVANTABIO | ₹15 Cr | — | ₹2 Cr | ₹1 Cr | 56.6% | ₹0 Cr | 6% | — | — | — |
Corporate actions, results dates and filings will appear here once ingested.
No scheme among the 32 fund houses on record reported a position in Adeshwar Meditex Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Documents link to external sources (exchange filings, company investor pages).
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 66 | 65 | 82 | 80 | 84 | 56 | |
| COGS | 55 | 55 | 70 | 70 | 74 | 47 |
| Gross profit | 11 | 10 | 13 | 10 | 9 | 9 |
| 7 | 6 | 8 | 5 | 5 | 6 | |
| Operating profit (EBITDA) | 5 | 3 | 5 | 5 | 4 | 3 |
| OPM % | 7% | 5.2% | 6.3% | 6.5% | 5.2% | 4.9% |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 0 |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | 2 | 1 | 3 | 3 | 3 | 2 |
| Tax | 1 | 0 | 1 | 1 | 1 | 1 |
| Tax % | 28.2% | 33.6% | 28.6% | 28% | 26.2% | 31.2% |
| 2 | 1 | 2 | 2 | 2 | 1 | |
| PAT margin % | 2.6% | 1.2% | 2.5% | 2.5% | 2.5% | 2.3% |
| EPS (₹) | 1.6 | 0.6 | 1.4 | 1.4 | 1.4 | 0.9 |
| Annual report | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | — | — | — | — | — | — |
| Reserves | — | — | — | — | — | — |
| Borrowings | — | — | — | — | — | — |
| 62 | 73 | 67 | 64 | 72 | 50 | |
| Total equity & liabilities | 62 | 73 | 67 | 64 | 72 | 50 |
| Fixed assets | — | — | — | — | 3 | 3 |
| CWIP | — | — | — | — | — | — |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 62 | 72 | 67 | 64 | 69 | 48 | |
| Total assets | 62 | 73 | 67 | 64 | 72 | 50 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 3 | -2 | 6 | 1 | 4 | 5 | |
| 1 | -1 | -1 | 0 | 1 | 0 | |
| -3 | 4 | -5 | -1 | -3 | -7 | |
| Net cash flow | 1 | 1 | -0 | 1 | 2 | -2 |
| Free cash flow | 3 | -4 | 6 | 1 | 4 | 5 |
| CFO / Operating profit % | 69.4% | -72.2% | 114.5% | 28.8% | 87.2% | 180.1% |